Unfortunately, about 40 percent of adults in the United States will get a cancer diagnosis in their lifetime. Mostly everyone has a friend, family member or colleague who has battled cancer. The National Cancer Institute even asserts that about 14.5 million citizens in the U.S. had cancer in 2014. By the year 2024, this number is expected to increase to over 19 million. Thanks to advances in medicine being made by Tempus and similar companies, however, the future of cancer treatment is looking a bit more optimistic. Erik Lefkofsky is the cofounder of of Tempus, and Lefkosky is also one of the founders of Groupon. Tempus is shaping up to be a leader in data-enabled precision medicine.
It would stand to reason that since there was such a demand for the medical industry to develop EHR or electronic health records, that the healthcare world would be more familiar with modern technology; however, this has not been the case. Lefkosky had never had real experience with cancer treatment until his wife was diagnosed with breast cancer. He was surprised to learn about the work that still needed to be done in terms of digital technology and data collection in the world of healthcare. Even though a considerable amount of data is collected about patients and their medical treatments, there hasn’t been an efficient and easily accessed way to gather this information. That’s where Tempus comes in.
The company has very impressive objective: to change the way that patients receive cancer care. Tempus has developed a system that analyzes the molecular and clinical data of the patient. The organization is also committed to gathering data and scientific information that will hopefully get rid of cancer for good. Lefkosky and his wife are committed to furthering their cancer treatment efforts and improving the quality of life for cancer patients and their families.